Figure 4. Whole body silencing Lpcat3 expression has no effect on lipid and energy metabolism in HFD-fed mice.

A-D. Serum triglyceride (A) and NEFA (B) levels and liver triglyceride (C) and NEFA (D) levels of HFD-fed C57BL/6 mice injected with Con-ASO or Lpcat3-ASO.
E. Expression of selected genes in the livers of HFD-fed C57BL/6 mice injected with Con-ASO or Lpcat3-ASO (n=12/group).
F. Postprandial lipid absorption analysis in HFD-fed C57BL/6 mice injected with Con-ASO or Lpcat3-ASO (n=4–5/group).
G. Representative histology of liver, eWAT and sWAT from HFD-fed C57BL/6 mice injected with Con-ASO or Lpcat3-ASO. Scale bar: 100 μm.
H-I. Energy expenditure (EE) analyzed by regression analysis of covariance (ANCOVA).
J. EE estimated by univariate generalized linear model (GLM) with body mass set to 39.14 g (average body mass of Con-ASO or Lpcat3-ASO injected mice on HFD).
K-L. Physical activity (K) and respiratory exchange ratio (RER) (L) in HFD-fed Lpcat3fl/fl mice injected with Con-ASO or Lpcat3-ASO.
Data are presented as means ± SEM. Statistical analysis was performed with Student’s t test (A-E), ANCOVA (H-I), and two-way ANOVA (F, J-L). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.